| Literature DB >> 26461145 |
Matthew Collin1, Venetia Bigley1, Kenneth L McClain2, Carl E Allen3.
Abstract
Langerhans cell histiocytosis (LCH) is heterogeneous disease characterized by common histology of inflammatory lesions containing Langerin(+) (CD207) histiocytes. Emerging data support a model in which MAPK activation in self-renewing hematopoietic progenitors may drive disseminated high-risk disease, whereas MAPK activation in more differentiated committed myeloid populations may induce low-risk LCH. The heterogeneous clinical manifestations with shared histology may represent the final common pathway of an acquired defect of differentiation, initiated at more than one point. Implications of this model include re-definition of LCH as a myeloid neoplasia and re-focusing therapeutic strategies on the cells and lineages of origin.Entities:
Keywords: BRAF; Dendritic cell; Langerhans cell histiocytosis; MAPK signaling; Myeloid differentiation
Mesh:
Year: 2015 PMID: 26461145 PMCID: PMC4699587 DOI: 10.1016/j.hoc.2015.06.003
Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN: 0889-8588 Impact factor: 3.722